John H Griffin Selected Research

PAR-1 Receptor

12/2018	Activated protein C, protease activated receptor 1, and neuroprotection.
1/2018	SCH79797 improves outcomes in experimental bacterial pneumonia by boosting neutrophil killing and direct antibiotic activity.
1/2018	The TLR4-PAR1 Axis Regulates Bone Marrow Mesenchymal Stromal Cell Survival and Therapeutic Capacity in Experimental Bacterial Pneumonia.
11/2016	2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C.
4/2013	Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1.
3/2009	Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality.
11/2008	Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1.
11/2006	Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John H Griffin Research Topics

Disease

28	Hemorrhage 01/2021 - 04/2003
26	Ischemic Stroke 01/2022 - 09/2002
26	Thrombosis (Thrombus) 01/2021 - 06/2002
22	Stroke (Strokes) 01/2022 - 07/2002
20	Inflammation (Inflammations) 01/2021 - 02/2003
17	Venous Thrombosis (Deep-Vein Thrombosis) 02/2020 - 08/2005
17	Sepsis (Septicemia) 01/2018 - 07/2002
9	Venous Thromboembolism 01/2018 - 03/2007
8	Infarction (Infarctions) 01/2022 - 04/2003
8	Ischemia 01/2022 - 06/2003
7	Endotoxemia 11/2015 - 10/2007
6	Reperfusion Injury 01/2021 - 02/2006
4	Hemophilia A (Haemophilia) 01/2021 - 03/2016
4	Pulmonary Embolism 01/2021 - 09/2015
3	Edema (Dropsy) 01/2022 - 04/2003
3	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2022 - 04/2003
3	Wounds and Injuries (Trauma) 01/2022 - 10/2016
3	Infections 01/2021 - 04/2015
3	Pneumonia (Pneumonitis) 01/2018 - 09/2011
3	Lung Injury 01/2018 - 09/2011
3	Intracranial Hemorrhages (Intracranial Hemorrhage) 07/2016 - 11/2006
3	Hypoxia (Hypoxemia) 01/2016 - 04/2003
3	Activated Protein C Resistance (APC Resistance) 11/2015 - 04/2007
3	Embolic Stroke 09/2012 - 09/2005
3	Atherosclerosis 11/2011 - 08/2002
3	Dyslipidemias (Dyslipidemia) 09/2010 - 08/2005
3	Brain Ischemia (Cerebral Ischemia) 11/2008 - 05/2004
2	Myocardial Ischemia (Ischemic Heart Diseases) 01/2021 - 01/2021
2	Bacterial Pneumonia 05/2020 - 01/2018
2	Brain Injuries (Brain Injury) 01/2019 - 04/2003
2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2016 - 11/2009
2	Thromboembolism 04/2013 - 09/2009
2	Purpura Fulminans 04/2012 - 04/2007
1	Lung Neoplasms (Lung Cancer) 10/2022
1	Fibrosis (Cirrhosis) 01/2022
1	Peripheral Arterial Disease 01/2022
1	Choroidal Neovascularization 01/2021
1	Acute Radiation Syndrome 01/2021

Drug/Important Bio-Agent (IBA)

63	Protein CIBA 01/2021 - 06/2002
41	AnticoagulantsIBA 01/2021 - 06/2002
17	Thrombin FDA Link 01/2021 - 08/2002
12	Peptide Hydrolases (Proteases)FDA Link 01/2022 - 03/2003
12	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2021 - 09/2005
11	Endothelial Protein C ReceptorIBA 01/2022 - 03/2003
10	Neuroprotective AgentsIBA 01/2022 - 04/2003
9	Protein SIBA 01/2020 - 04/2003
8	PAR-1 ReceptorIBA 12/2018 - 11/2006
7	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2004
6	Thromboplastin (Tissue Factor)IBA 10/2019 - 09/2009
5	3K3A-APC proteinIBA 01/2022 - 12/2013
5	Myosins (Myosin)IBA 01/2021 - 10/2016
5	Serine Proteases (Serine Protease)IBA 01/2020 - 12/2004
5	LipidsIBA 10/2019 - 03/2004
4	Hemostatics (Antihemorrhagics)IBA 01/2022 - 01/2021
4	Factor Xa (Coagulation Factor Xa)IBA 01/2021 - 09/2015
4	Factor VaIBA 11/2020 - 09/2002
4	LipopolysaccharidesIBA 01/2020 - 01/2012
4	Therapeutic UsesIBA 01/2018 - 09/2004
4	HDL LipoproteinsIBA 04/2012 - 08/2005
3	Hemoglobins (Hemoglobin)IBA 01/2022 - 03/2009
3	Protein Isoforms (Isoforms)IBA 01/2021 - 09/2010
3	CytokinesIBA 01/2021 - 03/2018
3	ApolipoproteinsIBA 02/2020 - 08/2005
3	lipoprotein-associated coagulation inhibitor (TFPI)IBA 01/2020 - 01/2018
3	FibrinIBA 01/2020 - 09/2009
3	CoagulantsIBA 01/2020 - 09/2005
3	ThrombomodulinIBA 01/2019 - 01/2006
3	Blood Coagulation Factors (Coagulation Factor)IBA 01/2018 - 04/2015
3	factor V LeidenIBA 11/2015 - 04/2007
2	FIIaIBA 01/2021 - 11/2020
2	InterferonsIBA 01/2021 - 04/2015
2	NF-kappa B (NF-kB)IBA 01/2021 - 11/2006
2	Cardiac MyosinsIBA 01/2021 - 01/2021
2	InflammasomesIBA 01/2021 - 12/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 01/2020
2	AntigensIBA 01/2020 - 09/2002
2	Factor V (Coagulation Factor V)IBA 01/2016 - 04/2012
2	Biological ProductsIBA 11/2015 - 11/2014
2	Biomarkers (Surrogate Marker)IBA 09/2015 - 08/2008
2	Pharmaceutical PreparationsIBA 11/2014 - 01/2012
2	Blood Proteins (Serum Proteins)IBA 08/2013 - 05/2004
2	EndotoxinsIBA 04/2013 - 06/2009
2	oxidized low density lipoproteinIBA 09/2010 - 08/2005
2	EnzymesIBA 05/2007 - 09/2004
2	Apolipoprotein A-I (Apolipoprotein A1)IBA 03/2007 - 08/2005
1	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 01/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Factor IIaIBA 01/2021
1	recombinant FVIIa (rFVIIa)FDA Link 01/2021
1	InterleukinsIBA 01/2021
1	AntithrombinsIBA 01/2021
1	Heparin (Liquaemin)FDA LinkGeneric 01/2021
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2021

Therapy/Procedure

30	Therapeutics 01/2021 - 07/2002
3	Thrombectomy 01/2021 - 01/2018
3	Thrombolytic Therapy 02/2011 - 09/2005
1	Radiotherapy 10/2022
1	Ligation 01/2021